Ablynx « Terug naar discussie overzicht

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
[verwijderd]
0
[verwijderd]
0
Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
[verwijderd]
0
Op zoek naar overnamekandidaten in de biotech zoals Ablynx of Tigenix.
Conatus pharmaceuticals lijkt een overnameprooi te gaan worden beurskrant.com/2018/03/06/stijgingspo...
3 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
911,34  -0,57  -0,06%  14:29
 Germany40^ 18.712,30 -0,16%
 BEL 20 3.965,14 -0,39%
 Europe50^ 5.077,92 -0,02%
 US30^ 39.498,10 +0,13%
 Nasd100^ 18.214,40 +0,05%
 US500^ 5.226,71 +0,06%
 Japan225^ 38.335,00 +0,38%
 Gold spot 2.343,71 +0,30%
 EUR/USD 1,0796 +0,06%
 WTI 78,28 -1,16%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

JUST EAT TAKE... +5,87%
BAM +4,12%
Alfen N.V. +4,00%
OCI +3,86%
Air France-KLM +3,61%

Dalers

VIVORYON THER... -3,90%
ASR Nederland -2,88%
IMCD -2,43%
NN Group -2,12%
CTP -1,55%